Clinical Study

Trailblazer (I5t-Mc-Aaci): Assessment Of Safety, Tolerability, And Efficacy Of Donanemab In Early Symptomatic Alzheimer’S Disease

Posted Date: Jun 9, 2020

  • Investigator: Lawrence Goldstick
  • Type of Study: Drug

To assess the effect of donanemab versus placebo on clinical progression in participants with early symptomatic AD with demonstrated presence of tau pathology


Patients Must Be Between The Ages Of 60-85 Years Of Age Who Have A Gradual Change In Memory For At Least 6 Months.


Alzheimers Disease, Dementia, Donanemab

For More Information:

Sarah Ross